rosiglitazone has been researched along with Lung Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Gong, X; Li, C; Liu, J; Xu, Z; Zhang, H; Zhu, L | 1 |
| Cho, RL; Hsiao, LD; Lin, CC; Lin, WN; Wang, CY; Yang, CC; Yang, CM | 1 |
| Cho, RL; Hsiao, LD; Lin, CC; Tseng, HC; Yang, CC; Yang, CM | 1 |
| Chen, L; Chen, YJ; Feng, YL; Liu, DS; Liu, WJ; Ou, XM; Wang, T; Wen, FQ; Xu, D; Zhang, SF | 1 |
| Armstrong, M; de Langhe, S; Dill, E; Gelfand, EW; Irwin, D; Klemm, D; Koster, M; Majka, SM; Nozik-Grayck, E; Okamoto, M; Reisdorf, N; Stenmark, KR; Takeda, K; West, J; Wilder, J | 1 |
| Patel, S; Rehan, VK; Santos, J; Torday, JS; Wang, Y | 1 |
6 other study(ies) available for rosiglitazone and Lung Diseases
| Article | Year |
|---|---|
Exposure to traffic-related fine particulate matter 2.5 causes respiratory damage via peroxisome proliferator-activated receptor gamma-regulated inflammation.
Topics: Air Pollution; Animals; Bronchoalveolar Lavage Fluid; Humans; Inflammation; Inhalation Exposure; Lung; Lung Diseases; Male; Mice; Mice, Inbred BALB C; Particulate Matter; PPAR gamma; Rosiglitazone; Traffic-Related Pollution | 2022 |
Heme oxygenase-1 induction by rosiglitazone via PKCα/AMPKα/p38 MAPKα/SIRT1/PPARγ pathway suppresses lipopolysaccharide-mediated pulmonary inflammation.
Topics: AMP-Activated Protein Kinases; Animals; Gene Expression Regulation; Heme Oxygenase-1; Inflammation; Lipopolysaccharides; Lung Diseases; Male; Mice; Mice, Inbred ICR; p38 Mitogen-Activated Protein Kinases; PPAR gamma; Protein Kinase C-alpha; Rosiglitazone; Sirtuin 1; Up-Regulation; Vascular Cell Adhesion Molecule-1 | 2018 |
Haem oxygenase-1 up-regulation by rosiglitazone via ROS-dependent Nrf2-antioxidant response elements axis or PPARγ attenuates LPS-mediated lung inflammation.
Topics: Animals; Anti-Inflammatory Agents; Cell Line; Epithelial Cells; Heme Oxygenase-1; Humans; Hypoglycemic Agents; Lipopolysaccharides; Lung; Lung Diseases; Male; Mice, Inbred ICR; NF-E2-Related Factor 2; PPAR gamma; Reactive Oxygen Species; Rosiglitazone; Up-Regulation | 2018 |
Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates acrolein-induced airway mucus hypersecretion in rats.
Topics: Acrolein; Animals; Blotting, Western; Bronchoalveolar Lavage Fluid; Cytokines; Drug Interactions; Goblet Cells; Immunohistochemistry; Lung Diseases; Male; Mucin 5AC; NF-kappa B; PPAR gamma; Random Allocation; Rats; Rats, Sprague-Dawley; Respiratory Mucosa; Reverse Transcriptase Polymerase Chain Reaction; RNA; Rosiglitazone; Thiazolidinediones | 2009 |
Peroxisome proliferator-activated receptor-g agonist treatment increases septation and angiogenesis and decreases airway hyperresponsiveness in a model of experimental neonatal chronic lung disease.
Topics: Animals; Animals, Newborn; Bronchoconstriction; Cell Differentiation; Disease Models, Animal; Fibroblasts; Humans; Hyperoxia; Infant, Newborn; Infant, Newborn, Diseases; Lung; Lung Diseases; Mice; Mice, Inbred C57BL; Muscle, Smooth; Neovascularization, Physiologic; PPAR gamma; Respiratory System; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vasodilator Agents | 2009 |
Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, prevents hyperoxia-induced neonatal rat lung injury in vivo.
Topics: Actins; Anilides; Animals; Animals, Newborn; Cell Differentiation; Cells, Cultured; Female; Fibroblasts; Gene Expression; Hyperoxia; Lung; Lung Diseases; Lung Injury; Male; Membrane Proteins; Perilipin-2; PPAR gamma; Pregnancy; Pulmonary Alveoli; Pulmonary Surfactant-Associated Protein B; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2006 |